- Home
- HOWL
HOWL
Werewolf Therapeutics Inc.
as 04-11-2025 4:00pm EST
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $9.00 | AVG Volume (30 days): | 278.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.59 - $6.89 | Next Earning Date: | 05-02-2025 |
| Revenue: | $1,885,000 | Revenue Growth: | -90.55% |
| Revenue Growth (this year): | 8.22% | Revenue Growth (next year): | 525.00% |
Latest Werewolf Therapeutics Inc. News
HOWL Breaking Stock News: Dive into HOWL Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Simply Wall St.
a month ago
Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
GlobeNewswire
a month ago
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
Zacks
a month ago
Pacira (PCRX) Tops Q4 Earnings Estimates
GlobeNewswire
2 months ago
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
Simply Wall St.
2 months ago
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch
TipRanks
3 months ago
Werewolf Therapeutics provides business update, highlights 2025 outlook
Compare HOWL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HOWL Werewolf Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.